{"name":"Kaizen Bioscience Co.","slug":"kaizen-bioscience-co","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Amoxicillin potassium clavulanate","genericName":"Amoxicillin potassium clavulanate","slug":"amoxicillin-potassium-clavulanate","indication":"Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections","status":"marketed"}]}],"pipeline":[{"name":"Amoxicillin potassium clavulanate","genericName":"Amoxicillin potassium clavulanate","slug":"amoxicillin-potassium-clavulanate","phase":"marketed","mechanism":"Amoxicillin inhibits bacterial cell wall synthesis while clavulanic acid protects amoxicillin from degradation by bacterial beta-lactamases, extending its spectrum of activity.","indications":["Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOWXpSQmN4c2ZiZHpnRm8tZW1BMFNFMTJvQmZjX3p6dDhNM0VoU1FmS2g4LWQyX2lnNUVhck1fbnhsYmNmTUg0QzlkN0R5UVU3WFdXajlxbWZKZVkzSEctMFcyQk5oS2YwV0hxaDloYkJ3VkhMOWlTemJFX0lxOWUyY3gzUGVQOHRaN19Zd3RQLXFGV21aaXQ0?oc=5","date":"2025-07-14","type":"regulatory","source":"Yahoo Finance","summary":"Kaizen Biosciences Announces Multiple Abstract Acceptances and Presents Pediatric Antibiotic PK Data to ISOM; Targets FDA’s New CNPV Pathway Ahead of September NDA Filing - Yahoo Finance","headline":"Kaizen Biosciences Announces Multiple Abstract Acceptances and Presents Pediatric Antibiotic PK Data to ISOM; Targets FD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNLXNWWWVma3k5NWdHSHJiek16RDBnbnY5LXRyM1QweWZSeXhFeU9ZR0VtRGlQRG8yMVczZXFrVEpnRzJCWGhIbTZYRU5wYjdYWDJLcEo2cGdYWWUyRkZHU3Q1QmhsbWZqUXExRnQtbjl6ZmthelF3QjhaM185cEI1WFZQU3BqQ2gyc1piY3FvRHNjUFJ0MWJkTUFmZVFVU3pGb0pXdmFMWFA?oc=5","date":"2024-11-15","type":"pipeline","source":"BioSpace","summary":"Kaizen Bioscience Preparing Lead Asset for NDA Submission in 2025 - BioSpace","headline":"Kaizen Bioscience Preparing Lead Asset for NDA Submission in 2025","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}